A cellular model reflecting the phenotypic heterogeneity of mutant HRAS driven squamous cell carcinoma

Squamous cell carcinomas have a range of histopathological manifestations. The parameters that determine this clinically observed heterogeneity are not fully understood. Here, we report the generation of a cell culture model that reflects part of this heterogeneity. We have used the catalytic subunit of human telomerase hTERT and large T to immortalize primary UV‐unexposed keratinocytes. Then, mutant HRAS G12V has been introduced to transform these immortal keratinocytes. When injected into immunosuppressed mice, transformed cells grew as xenografts with distinct histopathological characteristics. We observed three major tissue architectures: solid, sarcomatoid and cystic growth types, which were primarily composed of pleomorphic and basaloid cells but in some cases displayed focal apocrine differentiation. We demonstrate that the cells generated represent different stages of skin cancerogenesis and as such can be used to identify novel tumor‐promoting alterations such as the overexpression of the PADI2 oncogene in solid‐type SCC. Importantly, the cultured cells maintain the characteristics from the xenograft they were derived from while being amenable to manipulation and analysis. The availability of cell lines representing different clinical manifestations opens a new tool to study the stochastic and deterministic factors that cause case‐to‐case heterogeneity despite departing from the same set of oncogenes and the same genetic background.

[1]  P. Thompson,et al.  The protein arginine deiminases: Structure, function, inhibition, and disease. , 2013, Biopolymers.

[2]  G. Linette,et al.  Histopathologic characteristics of therapy‐associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma , 2014, Journal of cutaneous pathology.

[3]  S. Frankel,et al.  Non-melanoma Skin Cancer , 2021, Surgical Oncology Manual.

[4]  M. Feltkamp,et al.  Human Beta‐papillomavirus infection and keratinocyte carcinomas , 2015, The Journal of pathology.

[5]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[6]  F. Watt,et al.  FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis. , 2012, Cancer research.

[7]  J. L. Smith,et al.  Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006 , 2011 .

[8]  D. Schadendorf,et al.  RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[10]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[11]  J. Martı́n-Caballero,et al.  MacroH2A1 Regulates the Balance between Self-Renewal and Differentiation Commitment in Embryonic and Adult Stem Cells , 2012, Molecular and Cellular Biology.

[12]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[13]  W. V. van Venrooij,et al.  Recombinant human monoclonal autoantibodies specific for citrulline-containing peptides from phage display libraries derived from patients with rheumatoid arthritis. , 2003, The Journal of rheumatology.

[14]  Qi-En Wang,et al.  DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma. , 2013, Endocrine-related cancer.

[15]  M. Tormo,et al.  Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk‐adapted protocols , 2014, Cancer.

[16]  A. Ariza,et al.  Primary Renal Cell Carcinoma in a Transplanted Kidney: Genetic Evidence of Recipient Origin , 2009, Transplantation.

[17]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[18]  J. Martı́n-Caballero,et al.  E-box-independent regulation of transcription and differentiation by MYC , 2011, Nature Cell Biology.

[19]  Y. Fukui Mechanisms behind signet ring cell carcinoma formation. , 2014, Biochemical and biophysical research communications.

[20]  Fiona M. Watt,et al.  Epithelial stem cells, wound healing and cancer , 2012, Nature Reviews Cancer.

[21]  P. Khavari,et al.  CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis , 2002, Nature Medicine.

[22]  O. Griffith,et al.  Identification of PADI2 as a potential breast cancer biomarker and therapeutic target , 2012, BMC Cancer.

[23]  S. Feldman,et al.  Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. , 2015, JAMA dermatology.

[24]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[25]  M. Simon,et al.  Peptidylarginine deiminase isoforms 1-3 are expressed in the epidermis and involved in the deimination of K1 and filaggrin. , 2005, The Journal of investigative dermatology.

[26]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[27]  A. McCullough RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors , 2013 .

[28]  C. Creppe,et al.  A Cbx8-Containing Polycomb Complex Facilitates the Transition to Gene Activation during ES Cell Differentiation , 2014, PLoS genetics.

[29]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[30]  T. Jacks,et al.  Sunburn and p53 in the onset of skin cancer , 1994, Nature.

[31]  Jeung-Hoon Lee,et al.  Expression and Functional Role of Sox9 in Human Epidermal Keratinocytes , 2013, PloS one.

[32]  D. Brash Roles of the transcription factor p53 in keratinocyte carcinomas , 2006, The British journal of dermatology.

[33]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[34]  P. Boukamp Non-melanoma skin cancer: what drives tumor development and progression? , 2005, Carcinogenesis.

[35]  S. Horibata,et al.  PAD2 overexpression in transgenic mice promotes spontaneous skin neoplasia. , 2014, Cancer research.

[36]  G. Kristiansen,et al.  Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours , 2008, Breast Cancer Research.

[37]  V. Petronic-Rosic,et al.  Update on immunohistochemical methods relevant to dermatopathology. , 2009, Archives of pathology & laboratory medicine.

[38]  S. Alowami,et al.  Signet ring squamous cell carcinoma–the forgotten variant: case report and review of the literature , 2011, Journal of cutaneous pathology.

[39]  Robert A. Weinberg,et al.  Creation of human tumour cells with defined genetic elements , 1999, Nature.

[40]  Remco Loos,et al.  Citrullination regulates pluripotency and histone H1 binding to chromatin , 2014, Nature.

[41]  J. Shay,et al.  H-Ras Expression in Immortalized Keratinocytes Produces an Invasive Epithelium in Cultured Skin Equivalents , 2009, PloS one.

[42]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.